Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
7,179,487
-
Total 13F shares
-
156,318
-
Share change
-
+12,667
-
Total reported value
-
$182,895
-
Price per share
-
$1.17
-
Number of holders
-
11
-
Value change
-
+$14,820
-
Number of buys
-
2
-
Number of sells
-
2
Institutional Holders of Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (CLDI) as of Q4 2025
As of 31 Dec 2025,
Calidi Biotherapeutics, Inc. - Common Stock, $0.0001 par value (CLDI) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
156,318 shares.
The largest 10 holders included
HighTower Advisors, LLC, VANGUARD GROUP INC, Belpointe Asset Management LLC, Farther Finance Advisors, LLC, UBS Group AG, BARRETT & COMPANY, INC., Tradewinds Capital Management, LLC, Reyes Financial Architecture, Inc., SBI Securities Co., Ltd., and CVA Family Office, LLC.
This page lists
11
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.